JAK1 and lung cancer: However, solid cancers including lung cancer lack such activating somatic mutations.23, 41 Nevertheless, clinical trials for lung AC patients were launched using JAK inhibitors ruxolitinib, in particular for patients with activating EGFR‐mutations upstream of JAK1 and JAK2 (NCT02155465, NCT02145637, NCT02917993, NCT03450330).